GeneralMedium•13 November 2026•
1 min read
European Commission Approves FREHEMGO for Adults and Children with Haemophilia A
Key Facts
1The European Commission granted marketing authorisation for FREHEMGO to treat congenital FVIII deficiency (haemophilia A) in adults and children.
The European Commission granted marketing authorisation for FREHEMGO (denecimig) to treat congenital FVIII deficiency, also known as haemophilia A, in both adults and children. GlobeNewswire reported that the drug is the first FVIIIa mimetic to offer flexible dosing schedules, allowing for weekly, bi-weekly, or monthly administration via a pre-filled pen.
The approval introduces a new prophylactic treatment option for patients with or without inhibitors, focusing on dosing flexibility to enhance patient adherence. This regulatory milestone coincides with economic data from November 13, 2026, showing EU annual employment change at 0.4% and a trade balance of -10.3 billion.